Sekisui Chemical Co Ltd
TSE:4204

Watchlist Manager
Sekisui Chemical Co Ltd Logo
Sekisui Chemical Co Ltd
TSE:4204
Watchlist
Price: 2 430 JPY 2.32% Market Closed
Market Cap: 1T JPY
Have any thoughts about
Sekisui Chemical Co Ltd?
Write Note

Earnings Call Transcript

Earnings Call Transcript
2020-Q3

from 0
K
Keita Kato
executive

Hello. This is Keita Kato, Representative Director, Senior Managing Executive Officer and Head of Business Strategy Department. Thank you for coming today despite your busy schedules.

Without further ado, I'd like to go straight into the presentation.

Foreign exchange rate assumptions for our third quarter results as well as the full year forecast are as described here. For the third quarter, the yen was JPY 109 against the dollar. The assumption for the fourth quarter is JPY 109 against the dollar as well.

Here is the overview of profits and losses for the third quarter on a 9-month cumulative basis. Despite the prolonged slump in the global market, especially in the automobile market and the negative impact of a stronger yen compared to the previous year, domestic businesses like the Housing business and the UIEP, Urban Infrastructure & Environmental Products business, progressed firmly. As a result, sales and operating income were roughly unchanged from the previous year. On the other hand, ordinary income increased due to an improvement in nonoperating income from equity method investment income and miscellaneous income.

Next, let's look at results by divisional company. The table on the left shows the results for the third quarter and the table on the right shows the results for 9 months.

The HPP, High Performance Plastics Company, in the third quarter, recorded a sales and profit decline due to the impact from the sluggish global automobile market as well as the impact from the consumption tax hike that led to a reactionary drop-off in the domestic industrial businesses, such as general-purpose tapes. On the other hand, the Housing Company secured an increase in sales and profits by offsetting the impact from natural disasters as well as making progress on leveling out sales as we did in the first half too. Sales and profits have increased significantly even on a 9-month basis.

Regarding the UIEP Company, general-purpose products for housing struggled as it was affected by the tax hike, sales of prioritized products that contribute to natural disaster countermeasures and the facilitation of construction increased. And operating income reached the same level as the previous year. On a 9-month basis, profits increased.

Next, let's look at the outlook for market conditions. The smartphone market performed in line with our October expectations, but we do not expect a rapid recovery going forward. As for automobiles, the global market for automobiles is trending lower than October expectations. We are still not seeing any signs of a recovery.

In the upper right, regarding new housing orders, we achieved minus 7% year-on-year in the third quarter. We continue to receive more orders compared to other companies. Domestic Naphtha prices are expected to be JPY 41,000 for Q3 as originally anticipated, and the outlook is an increase to JPY 45,000 in Q4.

Let's look at the second half forecast for sales and operating income by divisional company. On the right side, the difference from the numbers announced in October is shown. On a total company basis, profits were revised down by JPY 3 billion as the global market is expected to remain sluggish for the HPP Company. The forecast for total company second half operating profit is shown at the very bottom on the left side where it says Total. We forecast total profit at JPY 55.5 billion, an increase of JPY 2 billion year-on-year.

By company, we aim to increase profits in all segments including the Medical Business in the second half and aim for the second half record-high profits.

Next, let's look at the situation by quarter and by divisional company. The forecast for the fourth quarter, by company, are shown on the right-hand side. I will go through them one by one.

In HPP, we will focus on the recovery of the Electronics field, expansion of the Building and Infrastructure field, and in the Automobiles and Transportation field, we will focus on the expansion of high-performance products, such as interlayer films for head-up displays. Additionally, by controlling fixed cost, we will aim to return back to profit growth in Q4. In the Housing Company, we will continue to level out sales, secure a high level of operating income and aim to achieve the full year plan.

In UIEP, we aim to increase profits by further expanding prioritized products and overseas businesses, which are positioned as growth drivers. In the Medical Business, we will continue to expand sales of diagnostic reagents overseas, and in the pharmaceutical sciences business, we will capture demand that has been pushed back into the fourth quarter due to customer reasons and aim to return back to profit growth.

Here is an analysis of operating profit in the second half.

Regarding the bar graph on the right, consolidated basis change includes onetime expenses for the acquisition of SEKISUI AEROSPACE CORPORATION as well as one-off costs regarding the integration of the U.S. plant that produces secondary structures like ducts. We also anticipate impacts from production cuts from the aircraft manufacturer customer.

Regarding sales quantity and composition, the breakdown of the difference is shown in the box. We will not achieve the target with the majority coming from HPP, however, we still expect an increase in profits year-on-year. On the other hand, we are working to further curb fixed costs and benefit from lower raw material prices, so as to achieve this plan. As a result, we expect to see an increase in sales and profits in the second half by offsetting the temporary increase in consolidation-related onetime costs, and the negative impact from foreign exchange rates.

Next, let's look at the full year net sales and operating income forecasts by divisional company. As shown in the middle, we aim to increase sales and profits in all segments except for HPP, and we aim to achieve the highest annual profits in the UIEP and Medical segments. We will also promote the selection and concentration of company-wide R&D themes, so as to contribute to improved profits. As a result, the company aims to increase operating income by JPY 1.3 billion to JPY 97 billion for the full year.

Here are the forecasts for the entire company in fiscal year 2019. Operating income has been revised down by JPY 3 billion, but we aim to grow top line so that we can achieve our targets for net sales, ordinary income and net income. Ordinary income and net income will reach record highs if achieved. In particular, net profit is expected to reach record highs for the seventh consecutive year.

From here on, I will explain second half forecasts by company. As explained earlier, operating income forecast for the HPP Company has been revised down by JPY 3.4 billion, due to the effects of the prolonged stagnation of the global automobile market, exchange rates and new consolidation. Our plan is to get back to profit growth, offsetting the negative impact from consolidated basis changes and currency with lower raw material costs, fixed cost reduction as well as a recovery in the Electronics field, an expansion in the Building and Infrastructure field and a recovery in domestic general-purpose products that was affected in the third quarter.

Let's look at the 3 strategic fields of the HPP Company. In the Electronics field, we recognize that it has bottomed out in the first half. We are seeing a recovery trend, mainly in the nonliquid crystal field centered around 5G and semiconductor-related materials. And we expect profits to increase in the second half and full year. In the field of Building and Infrastructure for CPVC, share increase and price increase are progressing due to the impact of anti-dumping regulations on competing countries by India. Thermal insulation and noncombustible materials continues to stay firm, and we expect higher sales and profits in the second half and full year.

In the Automobiles and Transportation field, high-performance interlayer films that have a high market share have been impacted by the slowdown in the global automobile market, but we still have been able to maintain our share. Interlayer film, for head-up displays, fell short of the plan but Q3 volume growth was up by more than 20% year-on-year, and we will focus on further expanding sales in the fourth quarter.

Next, I'd like to talk about the Housing Company. The Housing Company is progressing as planned in the second half. We have been able to make up for the natural disaster impact in October, and we are working to further level out sales in Q3 and 4. With regards to the number of housing units, we will not be able to reach plan due to the lack of construction in wake of the natural disasters and the impact of the consumption tax hike on apartment buildings and rebuilding. However, we are still expecting to increase housing sales by 100 units. We are also working to curb fixed costs, and we forecast that profits will reach record highs for the divisional company in the second half of the year as planned. Regarding the renovations business, the consumption tax hike is expected to affect both orders and sales but is expected to recover gradually.

This page is about new housing orders in the Housing Company. In the third quarter, there was a downturn in the number of visitors due to the impact of the natural disasters in October last year, and the consumption tax hike impact on rebuilding and apartment buildings affected orders to a certain extent. Still, we were able to keep orders at minus 7% compared to the previous year as we made efforts to strengthen sales of subdivision housing with land to first-time buyers and promoted smart houses. We believe that demand from first-time buyers will continue to be strong. So in Q4, we will further promote sales of land subdivision and expand sales of smart houses and will strive to keep orders flat year-on-year for detached houses at minus 1% year-on-year, which is broadly flat for total orders.

Next is the UIEP Company. In the second half in the domestic market, general-purpose products are expected to struggle due to a decline in demand after the consumption tax hike and the decrease in housing starts. However, we expect sales of prioritized products which contribute to natural disaster countermeasures, the facilitation of construction and infrastructure resilience to expand steadily. In the overseas business, the use of artificial wood, FFU, for railway sleepers is expanding and the sheet business is expanding for aircraft and medical use. In addition, we will reduce fixed costs and expect to achieve the profit plan as planned.

Next, I will explain the situation of 3 strategic areas of the UIEP Company. In the Piping and Infrastructure field, the decrease in demand for housing is expected to affect general-purpose products while nonresidential and public works construction pipe materials will continue to perform well, and sales are expected to increase. In the building and living environment fields, structural reforms are progressing as planned. And we expect to increase sales, excluding the impact of structural reforms.

In the Advanced Materials field, the sheet business struggled due to sluggish sales of general-purpose products for agricultural machinery and construction in the United States, but sales continues to steadily expand for airplanes and medical applications. The adoption of FFU, as railway sleepers, has been progressing steadily overseas and sales is expected to increase in the second half. The UIEP Company raises prioritized product sales and overseas sales as growth indicators and as shown in the graph on the lower right, both have been growing steadily.

Finally, let's look at the second half forecast of the Medical Business. In the third quarter, profits declined despite the steady expansion of the diagnostics business. There was a postponement in orders due to customer reasons in the pharmaceutical sciences business. We expect orders to recover in the pharmaceutical sciences business in Q4. And the diagnostics business is expected to continue to expand sales both in Japan and overseas with the expectation of achieving the operating income plan in the second half. As a result, we aim to achieve the highest annual profit in the Medical Business.

Details of our results are provided from the next page onwards. This ends my presentation. Thank you for your attention.